A response to: Vitamin D status may help explain survival disparities among racial/ethnic groups of women with ovarian cancer

Publication date: Available online 4 December 2019Source: Cancer EpidemiologyAuthor(s): Ashley E. Stenzel, Kirsten B. Moysich
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 25 January 2020Source: Process BiochemistryAuthor(s): Zehra Tavsan, Hulya Ayar KayaliAbstractThe interactions between the integrated complex array of integral and peripheral cell adhesion molecules (CAMs) are tightly controlled by kinases such as Protein Kinase C (PKC) in response to changes in external or internal forces and/or signaling. Focusing on the complex of EpCAM-claudin-tetraspanin-driven ovarian cancer, we described a sequence of events by which role of PKCs located in the tetraspanin enriched microdomains affected on the interactions and performed immunoprecipitations in PKC a...
Source: Process Biochemistry - Category: Biochemistry Source Type: research
ConclusionsChildren with cancer may be at risk for gonadal insufficiency. Ovarian tissue cryopreservation is mostly the only technique that can be offered for young girls. The procedure is safe and well accepted by the girls.
Source: Reproductive BioMedicine Online - Category: Reproduction Medicine Source Type: research
Molecules, Vol. 25, Pages 537: Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study Molecules doi: 10.3390/molecules25030537 Authors: Michalak Lach Antoszczak Huczyński Suchorska Polyether ionophore salinomycin (SAL) and its semi-synthetic derivatives are recognized as very promising anticancer drug candidates due to their activity against various types of cancer cells, including multidrug-resistant populations. Ovarian cancer is the deadliest among gynecologic malignancies, which is connected with the development of chemoresistant ...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
This study consisted of three parts: (1) in vitro experiments to establish the 'proof of principal' that combination of RFH and HSV-TK gene therapy has the synergistic effect on human ovarian cancer cells; (2) creation of bioluminescence imaging-detectable rat ovarian cancer model; and (3) in vivo experiments using this rat model to validate the technical feasibility of the combination therapy. Cells and nude rats were divided into four groups: (i) combination therapy (HSV-TK/GCV + RFH); (ii) RFH; (iii) HSV-TK/GCV; and (iv) phosphate-buffered saline (PBS). Data were analyzed using Dunnett t-test or ...
Source: International Journal of Hyperthermia - Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research
CONCLUSIONS: High YES1 cytoplasmic expression in EOC patient tissue is significantly correlated with favorable prognosis. Patients with high YES1 expression tend to be sensitive to platinum-based chemotherapy. PMID: 31970720 [PubMed - as supplied by publisher]
Source: Histology and Histopathology - Category: Cytology Tags: Histol Histopathol Source Type: research
Eleven genes have been identified that increase the lifetime risk of developing ovarian cancer. The cumulative cancer risk of ovarian cancer varies with the mutation type and age. Ovarian cancer risk management options include surgical risk reduction with salpingo-oophorectomy and a newer step-wise approach with interval salpingectomy and delayed oophorectomy. Women should be counseled on the pros and cons of hysterectomy in the setting of reducing the risk of other cancers; eliminating the risk of endometrial cancer in Lynch Syndrome, potential risk of serous/serous-like endometrial cancer in BRCA1 carriers, and eliminati...
Source: Clinical Obstetrics and Gynecology - Category: OBGYN Tags: New and Novel Treatments for Gynecologic Cancer Source Type: research
Treatment for patients with advanced ovarian cancer includes a combination of platinum-based chemotherapy and maximally cytoreductive surgery. The 2 options for initial treatment include upfront surgery followed by adjuvant chemotherapy or neoadjuvant chemotherapy followed by interval surgery. Deciding between which approach is a on the basis of several factors: (1) resectability of disease; (2) patient factors such as age, albumin, and body mass index; (3) patient wishes; and (4) overall functional status. Research is needed to further refine these approaches and create a patient-focused treatment plan which includes nove...
Source: Clinical Obstetrics and Gynecology - Category: OBGYN Tags: New and Novel Treatments for Gynecologic Cancer Source Type: research
Despite aggressive upfront treatment with a combination of surgery and chemotherapy, most women with advanced epithelial malignancy will experience disease recurrence. The goal of treatment in the recurrent setting shifts away from a curative approach towards palliation of symptoms. In an attempt to delay time to first recurrence, the concept of maintenance chemotherapy emerged. This paper reviews the available literature evaluating the use of maintenance chemotherapy in the primary treatment setting and its effect on progression-free survival and overall survival.
Source: Clinical Obstetrics and Gynecology - Category: OBGYN Tags: New and Novel Treatments for Gynecologic Cancer Source Type: research
A diagnosis of recurrent epithelial ovarian cancer carries with it a very poor prognosis despite aggressive chemotherapy with or without secondary surgical cytoreduction. Recently, maintenance treatment after second-line chemotherapy has gained momentum given promising results of antiangiogenics and PARP inhibitors used in this setting. When used appropriately, these agents may provide a meaningful survival benefit with minimal effects on quality of life. This paper reveals the current literature evaluating the use of maintenance therapy in the recurrent setting for the epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Source: Clinical Obstetrics and Gynecology - Category: OBGYN Tags: New and Novel Treatments for Gynecologic Cancer Source Type: research
Some of the patients with epithelial ovarian cancer will not respond to initial therapy. These patients have a poor prognosis. Our aim was to identify patients with a worse prognosis by integrating clinical, pathologic, and genomic data. Using publicly available genomic data and integrating it with clinical data, we significantly improved the prediction of patients with worse surgical outcomes and those who do not respond to initial chemotherapy. We further improved these models with more precise data collection and better understanding of the genetic background of the studied population. Better prediction will lead to bet...
Source: Clinical Obstetrics and Gynecology - Category: OBGYN Tags: New and Novel Treatments for Gynecologic Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Epidemiology | Ovarian Cancer | Ovaries | Vitamin D | Vitamins | Women